
Evotec is an R&D biotech company focused on accelerating drug discovery and development through collaborative partnerships. They offer pipeline co-creation, CRO/CDMO services, and leverage industrialized, AI-powered platforms like PanOmics and iPSC technologies. Their business model is based on flexible partnering and service agreements, aiming to bring medicines to patients efficiently. Evotec employs over 5000 people worldwide across 16 locations and works with pharmaceutical and biotech companies, academics, and patient advocacy groups.

Evotec is an R&D biotech company focused on accelerating drug discovery and development through collaborative partnerships. They offer pipeline co-creation, CRO/CDMO services, and leverage industrialized, AI-powered platforms like PanOmics and iPSC technologies. Their business model is based on flexible partnering and service agreements, aiming to bring medicines to patients efficiently. Evotec employs over 5000 people worldwide across 16 locations and works with pharmaceutical and biotech companies, academics, and patient advocacy groups.
Headquarters: Hamburg, Germany
Business: Integrated R&D biotech offering discovery-to-development services and co-created pipelines
Employees: ~4,800–5,000
Publicly listed: Yes (Frankfurt: EVT; Nasdaq: EVO)
Founded: 1993
Total funding (reported): USD 746,740,000 (multiple rounds, includes grants and post-IPO equity/debt)
Drug discovery and preclinical development (small molecules, biologics, cell therapies); therapeutic focus areas include oncology, cardiovascular/metabolic disease, neurology, and immunology.
1993
Biotechnology / Life Sciences / Drug Discovery
Latest listed funding event; company has multiple prior funding events including grants, post‑IPO equity and debt (16 rounds listed on Crunchbase).
“Evotec operates an EVOequity strategy and makes minority equity investments (documented investments include IMIDomics and Tubulis; participation in rounds of Exscientia).”